Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL145650 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13785162 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL29360959 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL3406205 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL34339 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1720497 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL40651 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL4740285 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1649712 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL2755938 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110649-A1 | COMBINATIONS OF LSD1 INHIBITORS AND MENIN INHIBITORS FOR TREATING CANCER | ORYZON GENOMICS, S.A. (ES) | 2024-05-30 | — | — | WO | disclosed |
| CN-117337281-A | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | 纽若平治疗公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023217758-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217784-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-11-16 | — | — | WO | disclosed |
| EP-3292100-B1 | SOLID FORMS | ORYZON GENOMICS SA (ES) | 2023-11-15 | — | — | EP | disclosed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| US-9918959-B2 | TLR-independent small molecule adjuvants | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017157825-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017157813-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| US-20170224653-A1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-10 | — | — | US | disclosed |
| US-20170224653-A1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-10 | — | — | US | disclosed |
| WO-2017060319-A1 | GENE EXPRESSION BIOMARKERS FOR PERSONALIZED CANCER CARE TO EPIGENETIC MODIFYING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| CN-103857393-B | Cyclopropylamine is as LSD1 inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103857393-A | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE LLC | 2014-06-11 | — | — | CN | disclosed |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2013-06-27 | — | — | US | disclosed |
| US-7566722-B2 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-28 | — | — | US | disclosed |
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | P2RY12, P2RY1, P2RY2 | MAOB 1571/4885MAOA 1911/4885KDM1A 3744/4885 |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | MAOB 610/4885MAOA 405/4885KDM1A 3290/4885 |
| US-20170224653-A1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | TLR1, TLR9, TLR3 | MAOB 3524/4885MAOA 3935/4885KDM1A 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.